Medication info
Lyrica New Capsule 75mg (Pregabalin)

Lyrica New Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a brownish-red upper part and a white lower part containing a white to light yellow powder.
Packaging
30 capsules per bottle
Approval status
Active

MFDS item code 201109294 · Approved 2011.10.31 · Insurance code 671805160

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also administered as an adjunct for patients with epilepsy who have partial seizures, regardless of the presence of secondary systemic symptoms. Furthermore, it helps alleviate symptoms of fibromyalgia. Therefore, this medication is used to improve pain and symptoms related to various neurological disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so depressive symptoms, mood changes, and unusual behavior should be closely monitored during treatment. Patients with hypersensitivity to this medication or genetic issues such as lactose intolerance should not take it. Diabetic patients need to be cautious about blood sugar control due to weight gain, and should discontinue use immediately if symptoms of angioedema occur. Elderly patients should be careful of the risk of falls due to dizziness or drowsiness, and any occurrences of blurred vision or changes in eyesight should be discussed with a doctor. Suddenly stopping this medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered gradually according to a doctor’s instructions. Due to the risk of drug abuse, patients with a history of substance abuse should be particularly cautious and report any signs of misuse immediately. Patients with heart disease or decreased kidney function should use this medication with caution, and dose adjustments may be necessary. Caution is advised when taking this medication with opioid analgesics due to the risk of central nervous system depression, and respiratory depression symptoms may occur, particularly in the elderly or those with kidney disease. During early pregnancy, there may be a risk of congenital malformations in the fetus, so pregnant women are advised not to take this medication, and fertile women should use effective contraceptive methods. During breastfeeding, as this medication may be passed into breast milk, discussions with a doctor are necessary to determine whether to continue breastfeeding or stop the medication. Before engaging in potentially dangerous activities such as driving or operating machinery, ascertain whether you are experiencing dizziness or drowsiness, and refrain from such activities if present. In rare cases, serious skin reactions may occur while taking this medication; if skin rashes, swelling, or fever develop, discontinue use immediately and consult medical personnel. In the event of an overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, necessitating immediate medical attention.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial edema
  • perioral edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 196 more
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • pain in limbs
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • sensation of intoxication
  • paresthesia
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • reduced serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • mood swings
  • emotional depression
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of inhibition
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention deficiency
  • memory impairment
  • tremors
  • speech disorders
  • sensory disturbances
  • sensory decrease
  • sedation
  • excessive drowsiness
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonic jerks
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • posture-related dizziness
  • sensory overreactivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • motion retardation
  • olfactory disturbances
  • loss of taste
  • writing disorders
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eyelid edema
  • reduced vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • changes in perception of visual depth
  • strabismus
  • brightness of fields of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusional state
  • agitation
  • restlessness
  • worsening of seizures
  • sleep disturbances
  • skin disorders
  • blood in stool
  • elevated BUN
  • tinnitus
  • gastrointestinal disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, at room temperature between 15 to 30 degrees Celsius. Proper storage helps maintain the medication’s effectiveness and prevents degradation.

Appearance and packaging

Appearance

A hard capsule with a brownish-red upper part and a white lower part containing a white to light yellow powder.

Package unit

30 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.